News

Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.

Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...

In a post on LinkedIn on Monday, Angelos Stergiou said despite speculation and outside commentary ‘naturally’ increasing, the company will let the data speak for itself.

An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.

Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.

Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.

Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.

A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.

The stock has gained over 20% in the past five days, marking its best week since early July.

SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results showing a net loss of US$9.61 million and basic loss per share from continuing operations of US$0.05, with first-half 2026 net loss reaching US$18.01 million and basic loss per share of US$0.10. Despite wider net losses in dollar terms, the company’s loss per share narrowed year on year, pointing to the impact of share count changes amid heightened interest in its Phase 3 GPS cancer vaccine program following positive...

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

SELLAS Life Sciences Group stock has posted a very large 3 year return while the latest valuation checks flag it as expensive rather than a clear bargain. Over the past 3 years, SELLAS Life Sciences Group has delivered a gain of about 7.9x, which sets a high bar for any further upside to be justified. Progress toward key milestones in the REGAL AML trial and the advancement of SLS009 in difficult cancer indications can support high growth expectations, yet the usual risks around clinical...

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.

A separate pediatric study delivered “striking” WT1 vaccine results, supporting GPS’s scientific rationale, the company's CEO said.

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.

Alliance Global lifted its SLS price target to $35 from $25, implying nearly 200% upside, and maintained a ‘Buy’ rating.